StockData

MediciNova vs SciSparc

MNOV and SPRC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MNOV and SPRC compare

MediciNova keeps more of each dollar of sales as profit, with a net margin of −1127% compared with −1423% at SciSparc.

MediciNova scores higher on the StockData Score (7 against 3 for SciSparc), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMNOVSPRC
Size and price
Market cap$68.7M–
Share price$1.40$0.353
Change, 1 year−11.1%−98.6%
Change, 5 years−56.5%−100.0%
Beta (5Y)0.390.31
Employees63
StockData Score
Total score7 (better)3
Valuation score1 (better)0
Growth score01 (better)
Performance score1 (better)0
Health score5 (better)2
Dividend score00
Valuation
P/S73.4×–
P/B1.7×–
FCF yield−14.3%–
Growth
Revenue growth (TTM)–−34.5%
EPS growth (TTM)–−51.9%
EPS growth, 5Y average–36.4%
Profitability
Gross margin–73.7%
Operating margin−1232%−978% (better)
Net margin−1127% (better)−1423%
FCF margin−1048%–
Return on equity−24.8% (better)−770%
Return on invested capital−78.4%–
Financial health
Debt / equity0.000.09 (better)
Interest coverage–−1.0×
Current ratio8.75 (better)0.87
Altman Z-score−3.99–
Piotroski F-score23 (better)
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions10.5%–
Held by insiders12.8%15.6%
Insider net buying, 12 months−$1.7M−$4.6K (better)
Short interest, % of float0.66%22.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.